Akeso's 2024 Results: Strengthening Global Competitiveness And Transforming The Treatment Landscape With Bispecific Antibodies
Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.
Medical Dialogues16h
Bristol Myers Squibb receives positive EMA Committee opinion for Perioperative Opdivo plus Chemo in Resectable Non-Small Cell Lung Cancer plus PD-L1
Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
Scientists uncover how TBK1 and IKKε prevent premature cell death and inflammation
New research from the Kennedy Institute has revealed how two important proteins, TBK1 and IKKε, play a crucial role in ...
CURE2d
Favorable Initial Results in Phase 1 Trial for PD-L1 Resistant Tumors
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Precision Medicine Online2d
Krazati, Keytruda Score Median Progression-Free Survival of 27 Months in First-Line NSCLC
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...
Pharmabiz2d
Immutep doses first patient in its TACTI-004 phase III clinical trial in first line non-small cell lung cancer
Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...
Cancer’s “Master Switch” Blocked for Good in Landmark Study
Researchers discovered peptides that permanently block a key cancer protein once thought untreatable, using a new screening ...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 ...
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...
Researchers identify potential drug combinations to improve breast cancer treatment: Q&A with professor of pharmacology
Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...
Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
Taiwan News3d
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025
Proof of principle data from Phase I part of the Phase I/II trial of TG4050 in the adjuvant setting of head and neck cancer. All TG4050-treated patients remained disease-free after median follow-up of ...